Hovione Increases Production Capacity

Loures, Portugal (ots/PRNewswire) -

'One Site Shop' expands to respond to growing demands

Hovione announces plan to increase production capacity in oral
dosage forms in Portugal, to strengthen the integrated offering. New
commercial scale equipment for blending, tableting and coating will
complement existing development small scale equipment. This decision
to expand follows growing customer demand since, one year ago Hovione
started offering end-to-end solutions, from drug substance to drug
product, from the Loures site.

(Logo: https://mma.prnewswire.com/media/655774/Hovione_Logo.jpg )

As a specialist integrated CDMO, Hovione is increasingly being
chosen as a solution partner from Drug Substance (http://www.hovione.
com/products-and-services/contract-manufacturing-services/drug-substa
nce) to Drug Product (http://www.hovione.com/products-and-services/co
ntract-manufacturing-services/drug-product/continuous-manufacturing-d
rug). Hovione 'One Site Shop' allows customers to streamline their
supply chain, reduce time to market and benefit from seamless project
management. This increase in capacity will help Hovione customers to
consistently bring products faster to market.

"Hovione has a unique value proposition when it comes to
processing amorphous solid dispersions. Our Company has more than 15
years of experience in pharmaceutical spray drying and has produced
hundreds of batches for clinical trials and commercial supplies. Our
customers now see drug product manufacturing at the site where they
produce their drug product intermediate as a natural extension of the
range of value added services they expect from us. They want to keep
their product in the same capable hands. This investment shows our
commitment to listen to our customers and continue to support their
evolving needs," says Frédéric Kahn Vice-President of Marketing &
Sales at Hovione.

In parallel Hovione will be completing by the end of 2018, the
qualification of its continuous tableting line (http://www.hovione.co
m/products-and-services/contract-manufacturing-services/drug-product/
continuous-manufacturing-drug) at Hovione New Jersey, which will
enable the site to offer end-to-end solutions for US customers that
are keen to keep their supply chain local.

The capacity expansion program started in 2016 and will continue
in the coming five years. In the first two years, Hovione has
relocated its development services to a new centre with 7.000 m[2] in
Lisbon, fully equipped with the most recent tools where Hovione is
able to handle potent and highly potent compounds. Globally within
our R&D we added new labs, new drug product centres, pilot plants and
our state-of-the-art particle engineering technologies (http://www.ho
vione.com/products-and-services/contract-manufacturing-services/parti
cle-engineering/technologies) both in the US and in PT. Locally, the
Loures site expanded its drug substance reaction vessel capacity with
a small-scale production area and a new pilot plant. We also
installed more spray drying capacity at the site and started the
operation of a new drug product centre equipped with oral dosage form
and inhalation manufacturing capabilities. In New Jersey, Hovione
doubled the size of its development and manufacturing operations. In
Cork we also expanded our chemical synthesis capacity devoted to
contract manufacturing.

Overall, Hovione's steadfast growth is the result of an integrated
synergy that allows the company to serve both the global markets and
also to respond to specific customers' demands whenever necessary. At
Hovione, we want to be the CDMO that customers like the most,
therefore we put the customers' needs at the centre of everything we
do relying on three growth pillars: operational excellence, customer
centricity and the team members' engagement.

About Hovione

Hovione has almost 60 years of experience as a Specialist
Integrated CDMO offering from drug substance to drug product
intermediate to drug product. With four FDA inspected sites in the
US, Macau, Ireland, and Portugal, and development laboratories in
Lisbon and New Jersey, the company provides branded pharmaceutical
customers services for the development and compliant manufacture of
innovative drugs and is able to support highly potent compounds. For
generic pharmaceutical customers the company offers niche off-patent
API products. In the inhalation area Hovione is the only independent
company offering a complete range of services. For further
information please visit http://www.hovione.com

Contact

Isabel Pina, Director of Corporate Communications

Tel.: 0035-121-982-9362 - ipina@hovione.com

ots Originaltext: Hovione
Im Internet recherchierbar: http://www.presseportal.de

Original-Content von: Hovione, übermittelt durch news aktuell